Results 41 to 50 of about 148,561 (252)
The Role of Clopidogrel in 2020: A Reappraisal
Cardiovascular Therapeutics, 2020 Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD).
Giuseppe Patti +3 more
doaj +1 more source
Ендоваскулярна нейрорентгенохірургія, 2020 Objective – to study the result of light transmission aggregometry with ADP for platelet reactivity before and after clopidogrel administration before extra-intracranial stenting. Materials and methods.
D.V. Shchehlov +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller +9 more
wiley +1 more source
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
Abrupt Cessation of One-Year Clopidogrel Treatment Is Not Associated With Thrombotic Events
Journal of Pharmacological Sciences, 2011 .: We aimed to examine the rate of thrombotic events after discontinuation of one year clopidogrel therapy in patients with implanted coronary stent, and to determine platelet aggregability by multiple electrode analyzer after cessation of clopidogrel ...
Nina Djukanovic +7 more
doaj +1 more source
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]
PLoS ONE, 2014 Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol +6 more
doaj +1 more source
Stroke genetics: prospects for personalized medicine.
, 2012 Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances, primarily using the genome-wide association study approach, are transforming what we know about the genetics of multifactorial stroke, and are identifying novel stroke ...
Markus Hugh S, Hugh S Markus, Markus, HS
core +1 more source
BMEMat, EarlyView.A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen +9 more
wiley +1 more source
PLoS ONE, 2013 BackgroundThe efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy. We investigated the efficacy and safety of
Tsung-Hsien Lin +9 more
doaj +1 more source
Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration
BMEMat, EarlyView.The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang +13 more
wiley +1 more source